207_Combined course Presentations

Conclusion (CMT in Stage III)

 Current standard regimens remain Carbo-tax and Cis-etoposide

 Testing of targeted agents in appropriate populations is long overdue – no clear indication to date

 Promising immune-therapy approaches are under investigation

 Prognostic and predictive factors are needed